These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37398209)

  • 1. A MICROGLIAL ACTIVITY STATE BIOMARKER PANEL DIFFERENTIATES FTD-GRANULIN AND ALZHEIMER'S DISEASE PATIENTS FROM CONTROLS.
    Pesämaa I; Müller SA; Robinson S; Darcher A; Paquet D; Zetterberg H; Lichtenthaler SF; Haass C
    bioRxiv; 2023 Jun; ():. PubMed ID: 37398209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer's disease patients from controls.
    Pesämaa I; Müller SA; Robinson S; Darcher A; Paquet D; Zetterberg H; Lichtenthaler SF; Haass C
    Mol Neurodegener; 2023 Sep; 18(1):70. PubMed ID: 37775827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C;
    Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations.
    Huang M; Modeste E; Dammer E; Merino P; Taylor G; Duong DM; Deng Q; Holler CJ; Gearing M; Dickson D; Seyfried NT; Kukar T
    Acta Neuropathol Commun; 2020 Oct; 8(1):163. PubMed ID: 33028409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum.
    Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D
    Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
    Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
    Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency.
    Reifschneider A; Robinson S; van Lengerich B; Gnörich J; Logan T; Heindl S; Vogt MA; Weidinger E; Riedl L; Wind K; Zatcepin A; Pesämaa I; Haberl S; Nuscher B; Kleinberger G; Klimmt J; Götzl JK; Liesz A; Bürger K; Brendel M; Levin J; Diehl-Schmid J; Suh J; Di Paolo G; Lewcock JW; Monroe KM; Paquet D; Capell A; Haass C
    EMBO J; 2022 Feb; 41(4):e109108. PubMed ID: 35019161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease.
    Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J
    Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
    Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
    Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
    Bos I; Vos S; Vandenberghe R; Scheltens P; Engelborghs S; Frisoni G; Molinuevo JL; Wallin A; Lleó A; Popp J; Martinez-Lage P; Baird A; Dobson R; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Bertram L; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Visser PJ
    Alzheimers Res Ther; 2018 Jul; 10(1):64. PubMed ID: 29980228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
    Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
    Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the minimal active soluble TREM2 sequence for modulating microglial phenotypes and amyloid pathology.
    Sheng X; Yao Y; Huang R; Xu Y; Zhu Y; Chen L; Zhang L; Wang W; Zhuo R; Can D; Chang CF; Zhang YW; Xu H; Bu G; Zhong L; Chen XF
    J Neuroinflammation; 2021 Dec; 18(1):286. PubMed ID: 34893068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.
    Takahashi H; Klein ZA; Bhagat SM; Kaufman AC; Kostylev MA; Ikezu T; Strittmatter SM;
    Acta Neuropathol; 2017 May; 133(5):785-807. PubMed ID: 28070672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
    Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer's Disease.
    Španić Popovački E; Babić Leko M; Langer Horvat L; Brgić K; Vogrinc Ž; Boban M; Klepac N; Borovečki F; Šimić G
    Neurol Int; 2023 Jul; 15(3):842-856. PubMed ID: 37489359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.